7036 Phase II study with pharmacodynamic evaluation of docetaxelprednisone (DP) in combination with metronomic cyclophosphamide (CTX) and celecoxib (C) as first line treatment in castration resistant prostate cancer (CRPC)

✍ Scribed by Fontana, A.; Galli, L.; Derosa, L.; Minuti, G.; D'Arcangelo, M.; Bursi, S.; Landi, L.; Bocci, G.; Santini, D.; Falcone, A.

• Book ID: 122805817
• Publisher: Elsevier Science
• Year: 2009
• Tongue: English
• Weight: 50 KB
• Volume: 7
• Category: Article
• ISSN: 1359-6349
• DOI: 10.1016/S1359-6349(09)71414-4